Skip to main content

Advertisement

Log in

Chronic Proton Pump Inihibitor Therapy and Calcium Metabolism

  • Stomach and Duodenum (J Pisegna, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Proton pump inhibitors (PPIs) have been widely used since their introduction in the late 1980s because they are highly effective for acid-related conditions. However, some recent epidemiological studies have suggested a positive association between PPI therapy and the risk of osteoporotic fractures. The potential mechanisms underlying this association may be related to the physiologic effects of chronic acid suppression on calcium metabolism. First, chronic hypergastrinemia induced by PPI therapy may lead to parathyroid hyperplasia, resulting in increased loss of calcium from the bone. Second, profound gastric acid suppression may reduce the bioavailability of calcium for intestinal absorption. I will review the published evidence regarding these potential links and discuss their clinical implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002;50:1644–50.

    Article  PubMed  Google Scholar 

  2. Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact.[erratum appears in Arch Intern Med 1922 Mar;152(3):655]. Arch Intern Med. 1991;151:2026–32.

    Article  PubMed  CAS  Google Scholar 

  3. Hetzel DJ. Controlled clinical trials of omeprazole in the long-term management of reflux disease. Digestion. 1992;51:35–42.

    Article  PubMed  Google Scholar 

  4. DeVault KR, Castell DO, American College of G, et al. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200.

    Article  PubMed  Google Scholar 

  5. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database [see comments]. BMJ. 1998;317:452–6.

    Article  PubMed  CAS  Google Scholar 

  6. Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther. 1998;12:797–805.

    Article  PubMed  CAS  Google Scholar 

  7. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76–83.

    Article  PubMed  CAS  Google Scholar 

  8. Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.

    Article  PubMed  CAS  Google Scholar 

  9. de Vries F, Cooper A, Logan R, et al. Fracture risk in patients receiving concomitant bisphosphonate and acid-suppressive medication or bisphosphonate alone. Osteoporos Int. 2007;18:S261.

    Article  Google Scholar 

  10. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures.[see comment]. CMAJ Can Med Assoc J. 2008;179:319–26.

    Article  Google Scholar 

  11. Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372.

    Article  PubMed  Google Scholar 

  12. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2011;170:765–71.

    Google Scholar 

  13. Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139:93–101.

    Article  PubMed  Google Scholar 

  14. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951–9.

    Article  PubMed  CAS  Google Scholar 

  15. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251–9.

    Article  PubMed  CAS  Google Scholar 

  16. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22:903–10.

    Article  PubMed  CAS  Google Scholar 

  17. FDA. Drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. 2010.

  18. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.[see comment]. J Clin Investig. 1999;104:439–46.

    Article  PubMed  CAS  Google Scholar 

  19. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550–5.

    Article  PubMed  CAS  Google Scholar 

  20. Stewart AF, Vignery A, Silverglate A, et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab. 1982;55:219–27.

    Article  PubMed  CAS  Google Scholar 

  21. Brunner G, Creutzfeldt W. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol - Suppl. 1989;166:101–5. discussion 11-3.

    Article  PubMed  CAS  Google Scholar 

  22. Brunner G, Creutzfeldt W, Harke U, et al. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion. 1988;39:80–90.

    Article  PubMed  CAS  Google Scholar 

  23. Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther. 1990;4:131–8.

    Article  PubMed  CAS  Google Scholar 

  24. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99:621–8.

    PubMed  CAS  Google Scholar 

  25. Lind T, Cederberg C, Forssell H, et al. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol. 1988;23:1259–66.

    Article  PubMed  CAS  Google Scholar 

  26. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis [see comments]. Gastroenterology. 1993;104:1356–70.

    PubMed  CAS  Google Scholar 

  27. Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci. 1991;36:552–7.

    Article  PubMed  CAS  Google Scholar 

  28. Hakanson R, Sundler F. Trophic effects of gastrin. Scand J Gastroenterol - Suppl. 1991;180:130–6.

    Article  PubMed  CAS  Google Scholar 

  29. Wang TC, Koh TJ, Varro A, et al. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Investig. 1996;98:1918–29.

    Article  PubMed  CAS  Google Scholar 

  30. Grimelius L, Johansson H, Lundqvist G, et al. The parathyroid glands in experimentally induced hypergastrinemia in the rat. Scand J Gastroenterol. 1977;12:739–44.

    Article  PubMed  CAS  Google Scholar 

  31. Gagnemo-Persson R, Hakanson R, Sundler F, et al. Growth of the parathyroid glands in omeprazole-treated chickens. Scand J Gastroenterol. 1994;29:493–7.

    Article  PubMed  CAS  Google Scholar 

  32. Gagnemo-Persson R, Samuelsson A, Hakanson R, et al. Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake. Calcif Tissue Int. 1997;61:210–5.

    Article  PubMed  CAS  Google Scholar 

  33. Cui GL, Syversen U, Zhao CM, et al. Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol. 2001;36:1011–5.

    Article  PubMed  CAS  Google Scholar 

  34. Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53:21–5.

    Article  PubMed  CAS  Google Scholar 

  35. Nordin BE. Calcium and osteoporosis. Nutrition. 1997;13:664–86.

    Article  PubMed  CAS  Google Scholar 

  36. Ensrud KE, Duong T, Cauley JA, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 2000;132:345–53.

    PubMed  CAS  Google Scholar 

  37. Nordin BE, O'Loughlin PD, Need AG, et al. Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures. Osteoporos Int. 2004;15:27–31.

    Article  PubMed  CAS  Google Scholar 

  38. Ervin RB, Wang CY, Wright JD, et al. Dietary intake of selected minerals for the United States population: 1999-2000. Advance Data 2004:1-5.

  39. Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol. 2004;160:339–49.

    Article  PubMed  Google Scholar 

  40. Champagne ET. Low gastric hydrochloric acid secretion and mineral bioavailability. Adv Exp Med Biol. 1989;249:173–84.

    Article  PubMed  CAS  Google Scholar 

  41. Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med. 1987;317:532–6.

    Article  PubMed  CAS  Google Scholar 

  42. Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313:70–3.

    Article  PubMed  CAS  Google Scholar 

  43. Chonan O, Takahashi R, Yasui H, et al. Effect of L-lactic acid on the absorption of calcium in gastrectomized rats. J Nutr Sci Vitaminol. 1998;44:869–75.

    Article  PubMed  CAS  Google Scholar 

  44. Chonan O, Takahashi R, Yasui H, et al. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol. 1998;44:473–81.

    Article  PubMed  CAS  Google Scholar 

  45. Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. Ann Intern Med. 1967;66:917–23.

    PubMed  CAS  Google Scholar 

  46. Nilas L, Christiansen C, Christiansen J. Regulation of vitamin D and calcium metabolism after gastrectomy. Gut. 1985;26:252–7.

    Article  PubMed  CAS  Google Scholar 

  47. Thompson J. The stomach and duodenum: Postoperative complications. Philadelphia: Saunders; 1991.

    Google Scholar 

  48. Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Investig. 1984;73:640–7.

    Article  PubMed  CAS  Google Scholar 

  49. Heaney RP, Smith KT, Recker RR, et al. Meal effects on calcium absorption. Am J Clin Nutr. 1989;49:372–6.

    PubMed  CAS  Google Scholar 

  50. Heller HJ, Greer LG, Haynes SD, et al. Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women.[erratum appears in J Clin Pharmacol 2001 Jan;41(1):116]. J Clin Pharmacol. 2000;40:1237–44.

    PubMed  CAS  Google Scholar 

  51. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10:1376–80.

    PubMed  CAS  Google Scholar 

  52. Graziani G, Badalamenti S, Como G, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron. 2002;91:474–9.

    Article  PubMed  CAS  Google Scholar 

  53. Hardy P, Sechet A, Hottelart C, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artificial Organs. 1998;22:569–73.

    Article  PubMed  CAS  Google Scholar 

  54. O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–81.

    Article  PubMed  Google Scholar 

  55. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14:364–8.

    PubMed  CAS  Google Scholar 

  56. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2011;25:2786–95.

    Article  Google Scholar 

  57. Heaney RP. Factors influencing the measurement of bioavailability, taking calcium as a model. J Nutr. 2001;131:1344S–8S.

    PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yu-Xiao Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, YX. Chronic Proton Pump Inihibitor Therapy and Calcium Metabolism. Curr Gastroenterol Rep 14, 473–479 (2012). https://doi.org/10.1007/s11894-012-0290-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-012-0290-4

Keywords

Navigation